Global Journal of Pharmacology 8 (1): 107-113, 2014 ISSN 1992-0075 © IDOSI Publications, 2014 DOI: 10.5829/idosi.gjp.2014.8.1.82122 Corresponding Author: Domnic Inbaraj, Department of Pharmacology, Sree Balaji Medical College and Hospital, Bharath University, Chromepet, Chennai-600044, India. 107 Comparative Study of Lipid and Glycemic Effects of Pioglitazone, Rosiglitazone with Glibenclamide in Patients with Type 2 Diabetes and Dyslipidemia S.D. Inbaraj and I . Glory Josephine Department of Pharmacology, Sree Balaji Medical College and Hospital, Bharath University, Chromepet, Chennai-600044, India Abstract: Objective: To evaluate the lipid and glycemic effects of Thiazolidinedione group of drugs (Pioglitazone, Rosiglitazone) in Type 2 diabetic patients with dyslipidemia.Methodogy: After ethical clearance and informed consent Type 2 diabetic patients with dyslipidemia attending the diabetic out patient clinic of Diabetology unit of Voluntary health services hospital.Chennai were screened and 45 patients selected for the study according to WHO criteria for diabetes and National cholesterol Education program guidelines for dyslipidemia. Each group consisting of 15 patients viz., Group I: Received Glibenclamide 5 mg/day. Group II: Received Pioglitazone 15 mg/day. Group III: Received Rosiglitazone 4 mg/day. Estimation of serum Total Cholesterol and HDL Cholesterol,Triglycerides,VLDL, Blood glucose,SGOT,S.GPT levels were estimated. Anthropometric evaluation and clinical parameters also evaluated. Results and discussion: Pioglitazone group showed significant reduction (p < 0.05) in fasting and post prandial blood glucose level at 12 week of study th when compared with sulphonylurea group. Reduction in total cholesterol level. 16% in pioglitazone, 4% in rosiglitazone and 1% in sulphonylurea group. Serum Triglycerides showed significant reduction (P< 0.001) in Rosiglitazone group when compared to sulphonylurea group at 12 week of the study. HDL cholesterol level th showed significant increase (p < 0.001) in pioglitazone group when compared to sulphonylurea group in 8 th week and 12 week of the study. LDL cholesterol level showed significant reduction (p < 0.05) in pioglitazone th group when compared to the Rosiglitazone group at 12 week of the study. When compared to pioglitazone, th Rosiglitazone showed considerable reduction (p < 0.05) at 4 and 8 week of the study. Liver enzymes study th th showed significant increase in SGOT and SGPT levels (p < 0.001) in pioglitazone as well as rosiglitazone group. Conclusion:Thiazolidinediones group of oral antidiabetic drugs shows hypoglycemic as well as favourable lipidemic effects on type 2 diabetic patients. Among the two glitazones, pioglitazone showed more favourable effects of increasing HDL cholesterol. Hence this group of drugs may be considered for use in the early stage of Type 2 diabetes judiciously to tide over the insulin resistance, hyperglycemia and dyslipidemia and thereby to prevent cardiovascular morbidity. Key words: Glitazones Pioglitazone Hypolipidemia Insulin Resistance INTRODUCTION The prevalence of type 2 diabetes is increasing Diabetes mellitus is a metabolic disorder of most important and costly disease[2]. India tops the multiple aetiology characterized by chronic word with largest number of patients. Presently India hyperglycaemia with disturbances of carbohydrates, has 32 million diabetic subjects and this will increase fat and protein metabolism resulting from defects in further to 57 million by 2025[3]. insulin secretion, insulin action, or both [1]. The important Type 2 diabetes patients often have metabolism affected by diabetes is the lipid metabolism other atherosclerotic risk factors such as which has the potential to develop atherosclerosis and dyslipidemia, obesity (Central obesity) hypertension, cardiovascular complications. etc. [4]. rapidly and it is destined to become one of the world’s